

# Heterogeneous T cell receptor V $\beta$ gene repertoire in murine interstitial nephritis

PETER S. HEEGER, WILLIAM E. SMOYER, MONICA JONES, SUELLEN HOPFER, and ERIC G. NEILSON

*Nephrology Section of the Department of Medicine, Cleveland VA Medical Center, Case Western Reserve School of Medicine, Cleveland Ohio; Pediatric Nephrology, University of Michigan Medical Center, Ann Arbor, Michigan; and Penn Center for Molecular Studies of Kidney Diseases, Renal-Electrolyte and Hypertension Division of the Department of Medicine, the Graduate Groups in Immunology and Cell Biology at the University of Pennsylvania, Philadelphia, Pennsylvania, USA*

**Heterogeneous T cell receptor V $\beta$  gene repertoire in murine interstitial nephritis.** Anti-tubular basement membrane disease ( $\alpha$ TBM) produces T cell-mediated interstitial nephritis in SJL/J mice following immunization with heterologous renal tubular antigen. Initial mononuclear infiltrates appear *in vivo* after six to eight weeks, with subsequent progression to renal fibrosis and endstage kidney disease. Cultured lymph node derived nephritogenic T cells from these mice react to a small epitopic region of the 3M-1 target antigen and share a common amino acid motif in their V $\beta$  CDR3 regions. We now have used RT-PCR to further characterize the renal expression of T cell receptor (TcR) V $\beta$  gene repertoires during the course of this disease. Individual kidneys with focal mononuclear infiltrates characteristic of early  $\alpha$ TBM disease express up to three different TcR V $\beta$  genes; however, the same V $\beta$  genes are not found in all kidneys at the same early stage of injury. DNA sequencing of the V $\beta$  RT-PCR products reveals a heterogeneous population of VDJ recombinations and deduced CDR3 amino acid sequences. Our studies do not support TcR V $\beta$  region gene restriction in histologically-detectable  $\alpha$ TBM disease, but are more consistent with a dynamic, organ-specific autoimmune disease, directed at multiple autoantigenic epitopes.

Analyses of T cell receptor (TcR) variable (V) region gene repertoires have provided important information regarding the basic pathophysiology of autoimmunity, and have resulted in specific immunotherapeutic interventions for the treatment of autoimmune diseases [1]. Initial studies performed in experimental allergic encephalomyelitis (EAE) showed that the TcR V $\beta$  gene repertoire of autoreactive, encephalitogenic T lymphocytes was highly restricted, and that specific anti-TcR V $\beta$ -region antibodies could successfully ameliorate progressive disease [2, 3]. Confirmation of this work by others led to formulation of the "V-region hypothesis," which suggests that a single epitope of a single antigen results in clonal expansion of a small number of autoreactive lymphocytes (all utilizing the same V-region), which then cause disease [4]. More recent work in both animals and humans has demonstrated that TcR V gene repertoires in autoimmune diseases may not be as restricted as originally anticipated [4–10]. There has been little published data, however, regarding the TcR V-region gene repertoire in autoimmune renal disease

[11, 12], and those studies that have been performed have focused on analysis of *in vitro* cultured T cell clones, not diseased kidneys [11, 12].

We have been studying a model of T cell-mediated autoimmune interstitial nephritis in mice, called anti-tubular basement membrane disease ( $\alpha$ TBM disease), which is induced by immunization with heterologous renal tubular antigen in complete Freund's adjuvant (RTA/CFA) [13, 14]. Initial T cell infiltration occurs after six to eight weeks, and progresses to interstitial fibrosis, end-stage renal disease and death within 16 to 20 weeks [13, 14]. The target antigen, 3M-1, is a 48 kDa glycoprotein found on the basolateral surface of proximal tubular epithelial cells [15, 16]. Prior studies have revealed that a 3M-1-reactive, MHC II-restricted, CD4<sup>+</sup> helper T cell initially emerges after immunization, but that this cell is unable to directly transfer disease [17]. Instead, the CD4<sup>+</sup> helper cell induces a 3M-1-reactive, MHC I-restricted, CD8<sup>+</sup> effector T cell that mediates delayed-type hypersensitivity (DTH), renal proximal tubular cytotoxicity, and is capable of directly transferring disease upon adoptive transfer to naive syngeneic animals [17–19].

Our recent interests have been focused on analysis of the TcR V gene repertoire of nephritogenic T cells in this disease model, in an attempt to identify potential targets for specific immunotherapeutic interventions. We have previously isolated and characterized a panel of nephritogenic CD4<sup>+</sup> helper T cell clones from peripheral lymph nodes of animals immunized to get  $\alpha$ TBM disease [12]. These T cell clones all recognize a single 14 residue immunodominant epitope contained within the target antigen, 3M-1 [12]. Analysis of TcR V $\beta$  gene usage by these clones revealed the presence of multiple V $\beta$  genes, with some preferential use of V $\beta$ 14, and evidence of common amino acid sequences across the putative CDR3 regions [12]. In order to extend these *in vitro* findings to a well-characterized *in vivo* model system, and to evaluate the TcR V $\beta$  gene repertoire within the diseased organs themselves, we have undertaken a semiquantitative reverse transcription polymerase chain reaction (RT-PCR) analysis of the TcR V $\beta$  gene repertoire throughout the course of anti-TBM disease.

## Methods

### Antigens

Rabbit renal tubular antigen (RTA) was isolated by previously published methods, and emulsified at 4 mg/ml with complete

Received for publication October 4, 1995  
and in revised form November 28, 1995  
Accepted for publication November 30, 1995

© 1996 by the International Society of Nephrology

Freund's adjuvant (2 mg/ml of purified protein derivative from Connaught Laboratories Ltd, Toronto, Ontario, Canada mixed with incomplete Freund's adjuvant purchased from Gibco BRL, Grand Island, NY, USA) to produce RTA/CFA.

#### Immunization

SJL mice (H-2<sup>s</sup>) four to six weeks of age (Jackson Laboratory, Bar Harbor, ME, USA) were immunized with RTA/CFA in multiple sites to get  $\alpha$ TBM disease. Some animals were immunized with CFA alone as controls.

#### Antibodies

Fluorescein (FITC)-conjugated and phycoerythrin (PE)-conjugated antibodies to murine CD3 [20], TcR V $\beta$ 2 [21], TcR V $\beta$ 4 [21, 22], TcR V $\beta$ 6 [21, 23], TcR V $\beta$ 7 [21, 24], and TcR V $\beta$ 14 [25] were purchased from Pharmingen (San Diego, CA, USA). FITC-conjugated anti-TcR V $\beta$ 8.1, 8.2 [26] was a kind gift of F. Heinzel (Dept. of Medicine, Cleveland VA Med Center, Cleveland, OH, USA).

#### Fluorescent activated cell sorter analysis (FACS) of peripheral lymphocytes

Pooled single cell suspensions of whole spleens were made after pushing each organ through a 60 mesh metal screen, and washing with DMEM/10% fetal bovine serum (Sigma, St. Louis, MO, USA). Enrichment for lymphocytes was performed by running the cell suspensions through Lympholyte-M (Cedar Lane Laboratories, Ltd., Hornsby, Ontario, Canada), as per the manufacturer's recommendations. One to  $2 \times 10^6$  cells were incubated with a 1:100 dilution of labeled antibody in 50  $\lambda$  of PBS/0.1% BSA for 30 minutes on ice. The cells were washed three times with phosphate buffer saline (PBS) 0.1% BSA, suspended in 1 ml of freshly made 1% paraformaldehyde, and stored covered in foil at 4°C. FACS analysis was performed on a Becton/Dickinson flow cytometer and analyzed with C30 software.

#### Organ harvest

At various time points after immunization, the animals were sacrificed, and the organs perfused with 30 milliliters of phosphate buffer saline (PBS) via intracardiac puncture, to eliminate peripheral blood contamination. Each kidney was divided in half: one portion was snap frozen and used for polymerase chain reaction (PCR) analysis of V $\beta$  genes, while the other portion was placed in formalin for histologic analysis. Slides were prepared and stained with hematoxylin and eosin by standard methods. Each slide was evaluated by a blinded investigator for the extent of disease involvement using the following scoring method: 0, no disease; 0.5, focal areas of lymphocytic infiltrates; 1, lymphocytic infiltrates in less than 10% of the renal cortex; 2, lymphocytic infiltrates in less than 25% of the renal cortex; 3, lymphocytic infiltrates comprising 50 to 75% of the renal cortex; 4, extensive infiltrates of greater than 75% of the renal cortex with tubular atrophy and scarring [17]. The spleen from each animal was also harvested and frozen for use in PCR experiments.

#### Polymerase chain reaction (RT-PCR) for TcR V $\beta$ genes


Total RNA was prepared from snap frozen kidney or spleen tissue using RNAsat (Tel-Test Inc., Friendswood, TX, USA) as per manufacturer's recommendations. Oligo dT-primed first

strand synthesis was performed with MMLV reverse transcriptase [27]. PCR was performed in 100  $\lambda$  total volume containing 10  $\lambda$  of 10 $\times$  buffer (Perkin-Elmer Cetus, Exton, PA, USA), 200  $\mu$ M dGTP, dCTP, dATP, dTTP, 0.25  $\lambda$  Taq polymerase (Perkin-Elmer Cetus), 1  $\mu$  of RNA/cDNA template, 40 pmol of 3' C $\beta$  antisense primer PH12 (5'-CTCAAACAAGGAGACCTTG3') and 40 pmol of 5' sense V $\beta$  region primer. The 5' V $\beta$  amplification primers for V $\beta$ 1-V $\beta$ 19 were derived by William Smoyer and Carolyn Kelly (University of Pennsylvania, Philadelphia, PA, and University of California San Diego, San Diego, CA, USA) using a matrix analysis (MacVector sequence analysis software for the Macintosh, IBI, New Haven, CT, USA) and the murine V $\beta$  gene sequences (manuscript in preparation). Each primer is a 20 mer designed to have minimal cross-reactivity to all other V $\beta$  region genes and encodes a product of unique predicted size. The V $\beta$ 20 primer was designed later from the published sequence using the same criteria, and has the following sequence: 5'-GCAGTTACACAGAAGCCAAG3'. Predicted sizes for PCR products using the 3' PH12 primer and each of the 5' V $\beta$  primers are as follows: V $\beta$ 1-387 bp, V $\beta$ 2-256 bp, V $\beta$ 3-250 bp, V $\beta$ 4-213 bp, V $\beta$ 6-373 bp, V $\beta$ 7-165 bp, V $\beta$ 10-355 bp, V $\beta$ 14-253 bp, V $\beta$ 15-394 bp, V $\beta$ 16-234 bp, V $\beta$ 17-319 bp, V $\beta$ 18-327 bp, V $\beta$ 19-312 bp, and V $\beta$ 20-376 bp. The actual sizes of each product vary by several base pairs secondary to N region additions and deletions. A master mix of all reagents except the 5' primers was made and divided into 14 tubes each containing one specific V $\beta$  region primer. A fifteenth control tube was run containing two constant region primers, 5'-C $\beta$  (5'-TACCCTTGTGTGCTTGGCCA3') and WS-2 (5'-GAACTGCACTTGGCAGC-GGA3'), encoding a predicted product of 207 bp. Amplifications were performed in a DNA thermal cycler (Perkin-Elmer Cetus) for 32 to 38 cycles at 92° denature for 60 seconds, 54° anneal for 60 seconds, and 72° elongation for 120 seconds.

#### Southern blots analysis of RT-PCR reactions

Fifteen percent of each RT-PCR product was run on a 1.2% agarose gel and transferred to a Magna NT nylon membrane (Fisher Scientific, Pittsburgh, PA, USA) with a Posiblot positive pressure blotting system (Stratagene, La Jolla, CA, USA) as per the manufacturer's recommendations. The blots were then denatured for 10 minutes with 0.4 M NaOH, washed in  $2 \times$  SSC and UV cross-linked (Stratalinker, Stratagene).

Four micrograms of a common internal C $\beta$  oligonucleotide, C $\beta$ int, (5'-GAGTCACATTTCTCAGATC3'), were end-labeled using 1 unit of polynucleotide kinase (Promega, Madison, WI, USA) 2  $\lambda$  of 10 $\times$  buffer, and 3  $\lambda$  of <sup>32</sup>P- $\gamma$ ATP (Amersham, Arlington Hts, IL, USA) in a 20  $\lambda$  volume for 45 minutes at 37°C. The labeled probe was separated from unincorporated nucleotides using a G25 spin column (Boehringer Mannheim, Indianapolis, IN, USA), as per the manufacturer's recommendations. Prehybridization was performed in  $6 \times$  SSC, 50 mM disodium phosphate pH 6.7, 5 $\times$  Denhardt's solution, 0.1 mg/ml boiled salmon sperm DNA at 37°C for a minimum of three hours. Hybridizations were performed in  $6 \times$  SSC, 50 mM disodium phosphate pH 6.7, 5 $\times$  Denhardt's solution, 0.1 mg/ml boiled salmon sperm DNA, 100 mg/ml dextran sulfate at 37°C with  $6 \times 10^5$ – $1 \times 10^6$  counts per milliliter of labeled probe, overnight. The blots were washed twice in  $6 \times$  SSC at 4°C for 30 minutes, then twice at 55°C for 20 minutes in 3 M TMAC, 50 mM Tris HCl pH 8.0, 2 mM EDTA, and 0.1% SDS. The blots were analyzed on a



**Fig. 1.** Effect of amplification cycle number on T cell receptor V $\beta$  RT-PCR products. **A.** Southern blots of V $\beta$  RT-PCR products from splenic RNA, probed with internal oligonucleotide C $\beta$ int, for 32, 35 and 38 cycles. **B.** Quantification of the individual bands from A, using the Bio Rad GS-250 Molecular Imager.

BioRad GS-250 Molecular Imager (BioRad Laboratories, Hercules, CA, USA) using PhosphorAnalyst software (BioRad Laboratories) for the Macintosh. After subtraction of the background, the density of each band was determined, and was expressed as a percentage of the total of all of the V $\beta$  regions for that organ. Statistical comparisons were performed using the Student's *t*-test. Some blots were additionally exposed to film and photographed.

#### Cloning and sequencing of V $\beta$ RT-PCR products

Equal aliquots of each of the 14 individual V $\beta$  RT-PCR products from selected diseased kidneys were mixed together, and shotgun cloned into the pCR 3000 TA cloning vector (In vitro, La Jolla, CA, USA) as previously described [28]. DNA plasmid preparations were performed on individual colonies using the Magic Miniprep kit (Promega), as per the manufacturer's recommendations. DNA sequencing was performed in both directions by the dideoxy chain determination method using fluorescein labeled primers as described by the manufacturer (Pharmacia, Uppsala, Sweden), and run on a Pharmacia LKB A.L.F. Automated Sequencing apparatus. Sequence analysis was done using the MacVector sequence analysis program for the Macintosh (IBI, New Haven, CT, USA).

#### Statistical analysis

Statistical comparisons were done using the Student's *t*-test.

## Results


### Optimization of the RT-PCR technique

Initial studies were performed to determine optimal parameters for amplification of each V $\beta$  PCR product. Figure 1 shows a representative experiment analyzing the effect of PCR cycle number on the peripheral V $\beta$  gene distribution using 1  $\mu$ g of splenic cDNA/RNA. Note that all of the PCR products are of predicted size, and bind to the internal primer (Fig. 1A). V $\beta$  genes deleted in SJL mice [29] were not detected by RT-PCR (data not shown). The relative density of each detected band, as quantified using a molecular phosphorimager, is graphically depicted in Figure 1B. The signal intensity for each V $\beta$  gene PCR product increases over the 32 to 38 cycle range, with the exception of V $\beta$ 2, which reaches a plateau after 35 cycles. Additionally, the relative percentage of each V $\beta$  PCR product, expressed as a fraction of all of the V $\beta$  products for that organ, is essentially identical at 32 and 35 amplification cycles (data not shown). We therefore performed all subsequent experiments with 1  $\mu$ g of RT product per reaction, 92°C for one minute, 54°C for one minute, and 72°C for two minutes, for 35 amplification cycles.

### Analysis of the peripheral TcR V $\beta$ gene repertoire in nonimmunized mice

To define the baseline peripheral TcR V $\beta$  gene repertoire, we performed RT-PCR for TcR V $\beta$  genes with splenic RNA isolated from multiple control (nonimmunized) animals (Fig. 2). Figure





**Fig. 2.** Peripheral T cell receptor V $\beta$  gene repertoire in unimmunized mice. **A.** Representative Southern blot of TcR V $\beta$  RT-PCR products from splenic RNA of an unimmunized animal. **B.** Relative quantity of each individual V $\beta$  RT-PCR product expressed as a percentage of the total of all V $\beta$  genes combined ( $N = 4$ ).

2A shows a representative autoradiograph of the peripheral TcR V $\beta$  gene repertoire from a normal animal, while Figure 2B graphically depicts the cumulative results of multiple experiments ( $N = 4$ ), and shows the relative expression of each V $\beta$  gene family as a percentage of the total of all V $\beta$  genes combined. SJL mice have a genomic deletion of a portion of the TcR V $\beta$  genes and thus do not express V $\beta$ 5, 8, 9, 11, 12, or 13 [29]. Spleens from unimmunized control animals contain transcripts for all nondeleted V $\beta$  genes, with V $\beta$ 2, 4, 6 and 17 comprising the highest individual percentages, while V $\beta$ 10, 15, 18, 19, 20 are present in significantly lower levels (Fig. 2B). This splenic TcR V $\beta$  gene repertoire did not change over the 20-week time period that animals were maintained in our animal facility (data not shown). Additionally, we studied multiple different shipments of mice, both male and female, born over an 18 months period, with similar findings (data not shown).

Using commercially available antibodies specific for individual TcR V $\beta$  gene families (PharMingen), we next studied selected V $\beta$  gene product expression on the surface of peripheral splenic lymphocytes. Figure 3 depicts a panel of two color FACS analyses evaluating the percentage of CD3 $^{+}$  splenic lymphocytes that additionally express V $\beta$ 2, 4, 6, 7, 8 and 14. Based on pooled lymphocytes from three individual spleens, 13.5% of CD3 $^{+}$  splenic cells express V $\beta$ 2, 13.9% express V $\beta$ 4, 10.7% express V $\beta$ 6, 10.5% express V $\beta$ 7, and 7.1% express V $\beta$ 14. V $\beta$ 8 $^{+}$  was not detected, as expected from the known genomic deletion of this element in SJL/J mice [29]. These numbers are similar to the distribution determined by PCR analysis (Fig. 2B), where V $\beta$ 2, 4, 6, 7, and 14 comprise 11.0%, 11.3%, 11.0%, 8.8%, and 6.5% of the total V $\beta$  genes, respectively.

#### Analysis of the peripheral V $\beta$ gene repertoire in immunized animals


We next wished to evaluate whether immunization producing  $\alpha$ TBM disease, or immunization with adjuvant alone, affects the peripheral V $\beta$  gene repertoire. Splenic TcR V $\beta$  gene expression 8 to 10 weeks after immunization with CFA alone, and after immunization with RTA/CFA to get  $\alpha$ TBM disease is shown in Figure 4, and demonstrates no significant differences between the two groups ( $P > 0.05$ ). Additionally, there are no significant differences ( $P > 0.05$ ) between the peripheral V $\beta$  gene repertoire of nonimmunized animals (Fig. 2B) and animals immunized with CFA alone or animals immunized with RTA/CFA to get disease (Fig. 4).

#### TcR V $\beta$ gene distribution in diseased kidneys


To minimize background blood contamination, each kidney was perfused with 30 ml of PBS via cardiac puncture, prior to harvest. This procedure routinely resulted in a visible blanching of the kidney, with no detectable blood in routine histologic sections. Figure 5 shows a photomicrograph of a normal kidney from an unimmunized animal, with an accompanying Southern blot of the RT-PCR for TcR V $\beta$  genes. As expected, there is minimal detectable TcR mRNA present in this normal organ, as compared to the splenic tissue. The strongest signals are V $\beta$ 2 and V $\beta$ 6, some of the same V $\beta$  genes that are expressed in the highest levels in the periphery (Fig. 2), and presumably reflect residual blood contamination and the high sensitivity of the RT-PCR technique. TcR V $\beta$  region gene analysis of histologically normal kidneys from animals immunized with adjuvant alone revealed similar findings (results not shown).

In contrast, kidneys with histologic grade 0.5 to 1 disease (focal mononuclear infiltrates in less than 10% of the renal cortex; Fig. 6A), predominantly express strong signals for up to three TcR V $\beta$  PCR products (Fig. 6B), with the remaining signals being comparable to the background levels found in the histologically normal kidneys. V $\beta$ 2, 6, and 7 are found in many of the kidneys with  $\alpha$ TBM disease, but other V $\beta$  region PCR products (3, 14 and 16) are present as well. No single V $\beta$  gene family is expressed preferentially in all kidneys. TcR V $\beta$  PCR products were not detectable above background in kidneys of animals immunized with RTA/CFA, prior to the histological detection of disease (data not shown).

Figure 7 shows the TcR V $\beta$  gene repertoire in kidneys with advanced  $\alpha$ TBM disease. A diseased kidney with typical grade 3 to 4 histology is shown in Figure 7A, and reveals a marked interstitial infiltrate with peritubular edema and early fibrosis. The TcR V $\beta$  genes found in 5 different kidneys with grade 3 to 4 histology are shown in Figure 7B, and reveals prominent expression of up to 10 different V $\beta$  gene products in any individual organ, with no discernible reproducible pattern of expression of any single V $\beta$  gene family. Notably, all of the organs were perfused with PBS prior to isolation of the RNA in order to minimize peripheral T cell contamination of the RT-PCR products. As can be seen, each of the TcR V $\beta$  gene distributions in Figure 7 differ from that found in the spleen (Fig. 2A), with some TcR V $\beta$  genes being totally absent, thus eliminating the possibility that the increased heterogeneity can be simply attributed to contaminating peripheral blood.




**Fig. 3.** TcR V $\beta$  gene product expression by peripheral lymphocytes. FACS analysis of splenic lymphocytes from unimmunized animals using PE-conjugated anti-CD3 (Y axis) and individual FITC-conjugated anti-V $\beta$  region antibodies (X axis). Splenocytes were pooled from three individual animals. The percentage of CD3+ T cells also expressing V $\beta$ 2, 4, 6, 7, 8, and 14 is 13.5%, 13.9%, 10.7%, 10.5%, 0%, and 7.1%, respectively.



**Fig. 4.** Peripheral T cell receptor V $\beta$  gene repertoire from immunized animals. Relative quantity of splenic V $\beta$  RT-PCR products expressed as a percentage of the total of all V $\beta$  genes combined. Black bars, animals immunized with CFA alone ( $N = 4$ ); striped bars, animals immunized with RTA/CFA ( $N = 7$ ). There are no statistically significant differences between groups, and no statistically significant differences between either group and the unimmunized animals (Fig. 2).



#### Sequence analysis of V $\beta$ gene products in early $\alpha$ TBM disease

To analyze the  $\beta$  chain CDR3 sequences across the VDJ junctions of the TcRs from the diseased organs, we next subcloned and sequenced individual RT-PCR products from two kidneys with histologically focal (early)  $\alpha$ TBM disease. For each kidney, two separate reverse transcription reactions, and four separate PCR reactions were used to generate the cDNA products used in the sequencing reactions. The deduced amino acid sequences are





**Fig. 5.** T cell receptor V $\beta$  RT-PCR products in normal renal tissue. **A.** Photomicrograph of normal kidney from an unimmunized mouse stained with hematoxylin and eosin (magnification 40 $\times$ ). **B.** Representative Southern blot of RT-PCR for V $\beta$  genes using RNA from a normal kidney.

shown in Table 1. For each sequence, the open reading frame confirms the presence of a known V $\beta$  and J $\beta$  gene. In both of the kidneys analyzed, there is a predominance of V $\beta$ 7 and V $\beta$ 3, although other V $\beta$  genes are present as well. The sequences from both organs also show some evidence for clonal expansion of individual T cell clones, in that several sequences were isolated from multiple different colonies, derived from different PCR reactions (Table 1). Several of the repeatedly isolated sequences from both organs contained V $\beta$ 3 and an n region encoded Arg



**Fig. 6.** T cell receptor V $\beta$  RT-PCR products in early  $\alpha$ TBM disease. **A.** Focal area of mononuclear cell infiltrate adjacent to histologically normal renal tissue in a kidney with grade 1  $\alpha$ TBM disease, stained with hematoxylin and eosin (magnification 40 $\times$ ). **B.** Southern blot of V $\beta$  RT-PCR products from 5 individual kidneys affected with histologic grade 0.5 to 1  $\alpha$ TBM disease.



**Fig. 7.** T cell receptor V $\beta$  RT-PCR products in extensive  $\alpha$ TBM disease. **A.** Extensive mononuclear cell infiltrate with tubular destruction and peritubular edema in a kidney with grade 3  $\alpha$ TBM disease. **B.** Southern blot of V $\beta$  RT-PCR products from 5 individual kidneys affected with histologic grade 3 to 4  $\alpha$ TBM disease.

residue. In fact, there is an overrepresentation of Arg residues encoded by n region additions/deletions in the sequences from both kidneys (Table 1). Interestingly, a similar n region encoded Arg (or structurally similar Lys or His residue) was found in many of the CDR3 $\beta$  chain sequences from our CD4 $^{+}$  nephritogenic T cell clones [12]. On the other hand, there is remarkable heterogeneity in both the length of the CDR3 regions as well as in the individual residues found within the regions. These findings hold true even among those sequences cloned from the same organ, and sharing the same V $\beta$  and J $\beta$  genes.

### Discussion

Initial studies of T cell receptor V $\beta$  gene expression in EAE [2, 3, 30], collagen arthritis [31, 32], and several other autoimmune disease models [reviewed in 33] suggested that autoreactive T cell repertoires are highly restricted. Based on such findings, many investigators hypothesized that autoimmunity was mediated by clonal expansion of a limited number of autoreactive T cells that recognize a single (or a few) determinant(s) derived from an

autoantigenic protein [1, 4]. In fact, DNA sequencing of TcR  $\beta$  chains from encephalitogenic T cell clones later revealed a recurrent amino acid residue motif across the CDR3 regions [34], further suggesting that autoimmune responses could be uniquely directed at a small number of epitopes. Other studies in EAE [5, 7], however, as well as analyses of NOD mice with diabetes [10] and thyroiditis [9] have revealed a more heterogeneous T cell receptor V $\beta$  gene repertoire. Additionally, studies of T cell receptor V region genes used in human autoimmune disease have yielded mixed findings; some cases of biased expression of TcRs have been noted [33, 35, 36], while others experiments suggest a more diverse repertoire [33, 37, 38].

Our studies are the first to comprehensively analyze the *in vivo* TcR V $\beta$  gene repertoire in any model of autoimmune renal disease. The results described herein reveal that the T cell receptors detected in kidneys affected by  $\alpha$ TBM disease are quite diverse, and suggest a polyclonal response. Although private repertoires of restricted TcR V $\beta$  gene families (containing up to three different V $\beta$  genes) are detectable in individual organs with



**Table 1.** TcR CDR3 $\beta$  sequences from kidneys with focal T cell infiltrates

A. Kidney 1				B. Kidney 2			
CDR3		V $\beta$ /J $\beta$		CDR3		V $\beta$ /J $\beta$	
CTCSA	P	SYNSPLYFAAGTRL	2/1.6	CTCS	<u>ADLGG</u>	AETLYFGSGTRL	2/2.3
CASS		LSGGL NYAEQFFGPGTRL	6/2.1				
CASS		QTGGAL AEQFFGPGTRL	4/2.1	CASS	<u>QETGGAL</u>	AEQFFGPGTRL	4/2.1
				CASS	<u>QEYN</u>	NYAEQFFGPGTRL	4/2.1 (2 colonies) <sup>a</sup>
CASS	<b>RDRG</b>	DTQYFGPGTRL	3/2.5 (4 colonies) <sup>a</sup>	CASS	<u>QDK</u>	DTQYFGPGTRL	4/2.5
CASS	<b>LSR RD</b>	SDYTFGSGTRL	3/1.2				
CAS	<b>RGQG</b>	YAEQFFGPGTRL	3/2.1	CASA	<b>IRDRG</b>	SDTQYFGPGTRL	6/2.5
CASS	<u>ARGF</u>	NSPLYFAAGTRL	3/1.6				
CASS	<u>QGVN</u>	ERLFFGHGHTKL	3/1.4 (2 colonies) <sup>a</sup>	CAS	<b>RWYT</b>	GQLYFGESESKL	3/2.2 (3 colonies) <sup>a</sup>
CASS	<u>IQGGQ</u>	NTLYFGAGTRL	3/2.4 (2 colonies) <sup>a</sup>	CASS	<b>ROGNNQAOH</b>	FGEGTRL	3/1.5
CASS	<u>LAV</u>	NQDTQYFGPGTRL	3/2.5	CASSL	<b>SR</b>	NYAEQFFGPGTRL	3/2.1 (2 colonies) <sup>a</sup>
CASS	<u>RQEAF</u>	GNTNYFGESESKL	3/1.3	CASS	<u>AGA</u>	NSDYTFGSGTRL	3/1.2
				CASS	<u>LKF</u>	SNERLFFGHGHTKL	3/1.4
				CASS	<u>LTGG</u>	NTLYFGAGTRL	3/2.4
CASS	<u>PGLG</u>	YAEQFFGPGTRL	7/2.1	CASSL	<u>TGS</u>	SPLYFAAGTRL	3/1.6
CA	<u>QSI</u>	QNTLYFGAGTRL	7/2.4	CASS	DN	SYEQYFGPGTRL	3/2.6
CASS	<u>LYI</u>	NTLYFGAGTRL	7/2.4				
CAS	<u>GYNQAOH</u>	FGEGTRL	7/1.5	CASS	<b>PNRGRD</b>	AEQFFGPGTRL	7/2.1
CASS	<b>ROGI</b>	TEVFFGKGTTRL	7/1.1	CASS	<b>LYRGI</b>	SNERLFFGHGHTKL	7/1.4
CASS	<u>ATF</u>	YAEQFFGPGTRL	7/2.1	CASS	<u>GLGS</u>	NQDTQYFGPGTRL	7/2.5
CASS	<b>LSGTK</b>	NQDTQYFGPGTRL	7/2.5	CASS	<b>LSR RG</b>	TGQTYFGESESKL	7/2.2
CASS	<b>LLI</b>	SAETLYFGSGTRL	7/2.3	CASS	<b>LEGASA</b>	ETLYFGSGTRL	7/2.3 (2 colonies) <sup>a</sup>

Standard single letter codes for amino acids are employed. Underlined residues are encoded by n region additions or deletions. Bold residues are positively charged arginine (R), histine (H), or lysine (K) residues encoded within the putative CDR3 regions.

<sup>a</sup> Multiple individual colonies contained identical sequences encoding these CDR3 regions

focal disease, and there is some evidence for clonal expansion of individual T cells, there is not an assured pattern of V $\beta$  expression in all organs tested. The heterogeneity of CDR3 $\beta$  sequences, despite the presence of shared V $\beta$  and/or J $\beta$  genes, confirms the polyclonal nature of the response. Moreover, further diversity is manifested as the disease progresses, as indicated by the increased numbers of detectable V $\beta$  genes by RT-PCR in kidneys with histologically more advanced lesions.

All of these findings must be interpreted in the context of known information about disease relevant autoantigens. Several published studies have noted that T cells expressing structurally distinct TcRs are capable of recognizing the same peptide/MHC complex [8, 10, 12, 38]. Previous work by our group has established that the autoreactive T cell and B cell repertoires in  $\alpha$ TBM disease are highly focused towards a single immunodominant region of the 3M-1 target antigen [12, 15, 39, 40]. We have shown that a panel of nephritogenic CD4<sup>+</sup> T cell clones, expressing a variety of TcR V $\beta$  genes (including V $\beta$ 14, V $\beta$ 3 and V $\beta$ 7), all recognize P3 (expressed in the context of I-A<sup>b</sup>), a peptide derived from 3M-1 [12]. Interestingly, these T cell clones expressed TcRs containing positively charged CDR3 $\beta$  regions, with an overrepresentation of Arg, Lys, or His residues encoded by n region additions or deletions [12]. Many of the TcR sequences derived from our diseased kidneys express V $\beta$ 3 and V $\beta$ 7, and also contain similar positively charged residues encoded by n region additions or deletions. These structural similarities suggest that some of the TcR sequences obtained from diseased kidneys could be derived from T cells reactive to P3.

Alternatively, the heterogeneous TcR repertoire could reflect T cells reactive to a number of antigenic epitopes. Other data from studies in EAE implicate a second autoantigen, proteolipid protein (PLP), in addition to myelin basic protein, as an important target of the encephalitogenic autoimmune response [41, 42]. The

description of autoreactive, pathogenic T cells recognizing multiple antigens, and several epitopes derived from each antigen, provides a reasonable explanation for the detection of a heterogeneous TcR V $\beta$  repertoire during active disease [41, 42]. In an analogous fashion, while P3 is an immunodominant determinant in the development of  $\alpha$ TBM disease [12], it remains possible that the renal expression of a diverse TcR V $\beta$  gene repertoire may reflect an immune response directed at other 3M-1-derived epitopes as well.

Progressively increasing heterogeneity of T cell receptor repertoires is also consistent with the recently described phenomenon of epitope spreading in autoimmunity [43, 44]. Epitope spreading is characterized by an initial autoreactive T cell response that is focused to a single (or a few) epitope(s), and that utilizes a restricted TcR V gene repertoire [43, 44]. The focused inflammatory reaction then leads to exposure of new antigenic epitopes, with up-regulation of costimulatory and chemoattractant molecules, eventually resulting in the influx of numerous T lymphocytes with specificities differing from the original disease-producing cells. This heterogeneous, newly infiltrating T cell population therefore expresses an expanded repertoire of TcR V $\beta$  genes [43, 44]. Our data suggest that the initial lymph node derived autoimmune response in  $\alpha$ TBM disease is focused towards P3 [12], and in individual animals, is initially biased towards selected V $\beta$  regions. As the disease progresses, the heterogeneity increases, consistent with the recruitment of T cells directed at additional antigens. Importantly, both intramolecular and intermolecular epitope spreading in murine EAE are prominently detectable at two to three weeks after immunization. Since  $\alpha$ TBM disease requires six to eight weeks to manifest itself histologically, it is conceivable that the autoreactive T cell response has spread to multiple autoantigenic epitopes by that time point.

The diversity of the T cell receptor repertoire may be partially

attributable to the fact that both CD4+ and CD8+ T cells are necessary for the phenotypic expression of  $\alpha$ TBM disease, and that both T cell subtypes have been identified in the renal infiltrates [14]. Although it remains possible that the T cell receptor repertoire of the CD4+ or CD8+ subpopulations derived from renal infiltrates may be more restricted, our previously published findings of T cell receptor V $\beta$  gene heterogeneity in CD4+, nephritogenic T cell clones argues that heterogeneity exists in at least the CD4+ subpopulation as well [28].

It is also possible that some of the increased heterogeneity of the TcR repertoire in severely diseased kidneys reflects recruitment of bystander lymphocytes attracted by nonspecific mediators of inflammation. Several studies in EAE have demonstrated the presence of nonspecific T cells in the brains or spinal cords of symptomatic animals [45–47], but the role played by nonspecific polyclonal infiltrates in autoimmune renal disease is unknown.

Importantly, we have defined the renal T cell receptor V $\beta$  gene repertoire based on the detection of RT-PCR products, and we cannot be certain that this truly reflects TcR protein expression on the surface of T cells infiltrating diseased renal tissue. However, the similarity between TcR V $\beta$  gene product expression by FACS and TcR V $\beta$  transcript level by RT-PCR (Figs. 2 and 3), suggests that RT-PCR can provide a reasonable approximation of the TcR V $\beta$  gene product repertoire *in vivo*.

These studies additionally define the baseline peripheral TcR V $\beta$  gene repertoire in SJL/J mice within the constraints of the 20 known V $\beta$  gene families, and allow for a comparison with the peripheral repertoire from diseased animals. The similarity between TcR V $\beta$  gene product expression by FACS and TcR V $\beta$  transcript level by RT-PCR, suggests that RT-PCR can provide a reasonable approximation of the TcR V $\beta$  gene repertoire *in vivo*. Our findings are additionally consistent with the relative expression of V $\beta$  genes detected by other investigators [29, 48]. Interestingly, the peripheral distribution of TcR V $\beta$  genes varies minimally between unimmunized animals, does not change over the 20 weeks during which the animals were maintained in our animal facility, and is not affected by immunization with adjuvant alone. Additionally, immunization with RTA/CFA has little effect on the relative expression of peripheral TcR V $\beta$  genes, even when the disease is present histologically in the kidney. It remains likely, however, that clonal expansion of individual T cells does occur peripherally in response to immunization with RTA/CFA, but that such expansion does not affect the overall T cell receptor repertoire of the animal.

In conclusion, these studies, in conjunction with those from our previously described, nephritogenic T cell clones [12], do not support a strict "V-region hypothesis" of T cell responses in murine  $\alpha$ TBM disease, and suggest that restricted T cell repertoires are not a generalizable phenomenon of all autoimmune diseases. T cells detected in diseased organs affected with  $\alpha$ TBM disease express heterogeneous T cell receptors, most consistent with a polyclonal response directed at multiple antigenic epitopes. The diversity of TcR V $\beta$  genes expressed in diseased kidneys, even in the early stages of disease, suggests that immunotherapy directed at individual V $\beta$  gene elements would not be efficacious in the prevention or treatment of this disease. Theoretically, even successful elimination of a single V $\beta$  gene family, using a specific anti-V $\beta$  region antibody, would leave a residual autoreactive T cell population capable of producing renal injury. Immunotherapeutic approaches targeting immunodominant epitopes [49], or targeting

common structural characteristics of the autoreactive TcRs within complementarily determining regions [50], may be more appropriate alternatives for the treatment of this disease entity.

### Acknowledgments

This work was supported, in part, by the Medical Research Service of the Department of Veterans Affairs, and by grants from the National Institutes of Health (DK-30280, DK-07006, DK-45191, DK-41110, DK-46282, DK-08446, and DK-42155). P.H. is a recipient of a Clinical Investigator Award (K08 DK-02125 to 01) from the National Institute of Health. W.S. is a recipient of a National Research Service Award (1 F32 DK 08607 to 01) from the National Institute of Health.

Reprint requests to Peter S. Heeger, M.D., Department of Medicine, 111K(W), Cleveland VA Medical Center, 10701 East Blvd., Cleveland, Ohio 44106, USA. E-mail: heeger.peter@cleveland.va.gov

### References

1. ACHA-ORBEA H, STEINMAN L, McDEVITT HO: T cell receptors in murine autoimmune diseases. *Ann Rev Immunol* 7:371–405, 1989
2. KUMAR V, KONO D, URBAN J, HOOD L: The T-cell receptor repertoire and autoimmune diseases. *Ann Rev Immunol* 7:657–682, 1989
3. URBAN JL, KUMAR V, KONO DH, GOMEZ C, HORVATH SJ, CLAYTON J, ANDO DG, SERCARZ EE, HOOD L: Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy. *Cell* 54:577–592, 1988
4. CAPRA J, NATVIG J: Is there V region restriction in autoimmune diseases? *The Immunologist* 1:1, 1993
5. BELL R, LINDSEY J, SOBEL R, HODGKINSON S, STEINMAN L: Diverse T cell receptor V beta gene usage in the central nervous system in experimental allergic encephalomyelitis. *J Immunol* 150:4085–4092, 1993
6. OKSENBERG J, PANZARA M, BEGOVICH A, MITCHELL D, ERLICH H, MURRAY R, SHIMONKEVITZ R, SHERRITT M, ROTHBARD J, BERNARD C, STEINMAN L: Selection for T-cell receptor V $\beta$ -D $\beta$ -J $\beta$  gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. *Nature (London)* 362:68–70, 1993
7. SU X, SRIRAM S: Analysis of TCR V beta gene usage and encephalitogenicity of myelin basic protein peptide p91–103 reactive T cell clones in SJL mice: lack of evidence for V gene hypothesis. *Cell Immunol* 141:485–495, 1992
8. SUN D, LE J, COLECLOUGH C: Diverse T cell receptor beta chain usage by rat encephalitogenic T cells reactive to residue 68–88 of myelin basic protein. *Eur J Immunol* 23:494–498, 1993
9. MATSUOKA M, BERNARD N, CONCEPCION E, GRAVES P, BEN-NUN A, DAVIES T: T-cell receptor V region  $\beta$ -chain gene expression in the autoimmune thyroiditis of non-obese diabetic mice. *J Immunol* 151: 1691–1701, 1993
10. NAKANO N, KIKUTANI H, NISHIMOTO H, KISHIMOTO T: T cell receptor V gene usage of islet  $\beta$  cell-reactive T cells is not restricted in non-obese diabetic mice. *J Exp Med* 173:1091–1097, 1991
11. ADAMS S, LEBLANC P, DATTA S: Junctional region sequences of T-cell receptor  $\beta$ -chain genes expressed by pathogenic anti-DNA autoantibody-inducing helper T cells from lupus mice: Possible selection by cationic autoantigens. *Proc Natl Acad Sci (USA)* 88:11271–11275, 1991
12. HEEGER P, SMOYER W, SAAD T, ALBERT S, KELLY C, NEILSON E: Molecular analysis of the helper T cell response in murine interstitial nephritis: T cells recognizing an immunodominant epitope use multiple TcR V $\beta$  genes with similarities across CDR3. *J Clin Invest* 94:2084–2092, 1994
13. NEILSON EG, PHILLIPS SM: Murine interstitial nephritis. I. Analysis of disease susceptibility and its relationship of pleiomorphic gene products defining both immune-response genes and a restrictive requirement for cytotoxic T cells at H-2K. *J Exp Med* 155:1075–1085, 1982
14. ZAKHEIM B, MCCAFFERTY E, PHILLIPS SM, CLAYMAN M, NEILSON EG: Murine interstitial nephritis. II. The adoptive transfer of disease with immune T lymphocytes produces a phenotypically complex interstitial lesion. *J Immunol* 133:234–239, 1984
15. NEILSON EG, SUN MJ, KELLY CJ, HINES WH, HAVERTY TP, CLAYMAN MD, COOKE NE: Molecular characterization of a major nephritogenic



- domain in the autoantigen of anti-tubular basement membrane disease. *PNAS (USA)* 88:2006–2010, 1991
16. HAVERTY TP, KELLY CJ, HINES WH, AMENTA PS, WATANABE M, HARPER RA, KEFALIDES NA, NEILSON EG: Characterization of a renal tubular epithelial cell line which secretes the autologous target antigen of autoimmune experimental interstitial nephritis. *J Cell Biol* 107:1359–1368, 1988
  17. MANN R, ZAKHEIM B, CLAYMAN M, MCCAFFERTY E, MICHAUD L, NEILSON EG: Murine interstitial nephritis. IV. Long-term cultured L3T4+ T cell lines transfer delayed expression of disease as I-A-restricted inducers of the effector T cell repertoire. *J Immunol* 135:286–293, 1985
  18. MANN R, KELLY CJ, HINES WH, CLAYMAN MD, BLANCHARD N, SUN MJ, NEILSON EG: Effector T cell differentiation in experimental interstitial nephritis. I. The development and modulation of effector lymphocyte maturation by I-J+ regulatory T cells. *J Immunol* 138:4200–4208, 1987
  19. MEYERS C, KELLY C: Effector mechanisms in organ-specific autoimmunity. I. Characterization of a CD8+ T cell line that mediates murine interstitial nephritis. *J Clin Invest* 88:408–416, 1991
  20. LEO O, FOO M, SACHS D, SAMELSON L, BLUESTONE J: Identification of a monoclonal antibody specific for a murine T3 polypeptide. *PNAS (USA)* 84:1374–1378, 1987
  21. SUGIHARA S, FUJIWARA H, SHEAVER G: Autoimmune thyroiditis induced in mice depleted of particular T cell subsets. *J Immunol* 150:683–694, 1993
  22. TOMONARI K, LOVERING E, SPENCER S: Correlation between the V $\beta$ 4+ CD8+ T cell population and the H-2<sup>d</sup> haplotype. *Immunogenetics* 31:333–339, 1990
  23. KANAGAWA O: In vivo T cell tumor therapy with monoclonal antibody directed to the V $\beta$  chain of the T cell antigen receptor. *J Exp Med* 170:1513–1519, 1989
  24. OKADA C, HOLZMANN B, GUIDOS C, PALMER E, WEISSMAN I: Characterization of a rat monoclonal antibody specific for a determinant encoded by the V $\beta$ 7 gene segment. *J Immunol* 144:3473–3477, 1990
  25. LAIO N, MALTZMAN J, RAULET D: Positive selection determines T cell receptor V $\beta$ 14 gene usage CD8+ T cells. *J Exp Med* 170:135–143, 1989
  26. KANAGAWA O: Antibody-mediated activation of T cell clones as a method for screening hybridomas producing antibodies to the T cell receptor. *J Immunol Meth* 110:169–178, 1988
  27. HEEGER P, WOLF G, MEYERS C, SUN MJ, KRENSKY A, NEILSON EG: Isolation and characterization of cDNA from renal tubular epithelium encoding Murine Rantes, a small intercrine from the Scy superfamily. *Kidney Int* 41:220–225, 1992
  28. HEEGER PS, SMOYER WE, SAAD T, ALBERT S, KELLY CJ, NEILSON EG: Molecular analysis of the helper T cell response in murine interstitial nephritis. *J Clin Invest* 94:2084–2092, 1994
  29. BEHLKE MA, CHOU HS, HUPPI K, LOH DY: Murine T-cell receptor mutants with deletions of beta-chain variable region genes. *PNAS (USA)* 83:767–771, 1986
  30. ACHA-ORBEA H, MITCHELL DJ, TIMMERMANN L, WRAITH DC, TAUSCH GS, WALDOR MK, ZAMVIL SS, MCDEVITT HO, STEINMAN L: Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. *Cell* 54:263–273, 1988
  31. OSMAN G, TODA M, KANAGAWA O, HOOD L: Characterization of the T cell receptor repertoire causing collagen arthritis in mice. *J Exp Med* 177:387–395, 1993
  32. HAQOI T, ANDERSON G, BANERJEE S, DAVID C: Restricted heterogeneity in T-cell antigen receptor V $\beta$  gene usage in the lymph nodes and arthritic joints of mice. *PNAS (USA)* 89:1253–1255, 1992
  33. GOLD D: TCR V gene usage in autoimmunity. *Curr Opin Immunol* 6:907–912, 1994
  34. GOLD D, OFFNER H, SUN D, WILEY S, VANDENBARK A, WILSON D: Analysis of T cell receptor  $\beta$  chains in Lewis Rats with experimental allergic encephalomyelitis: Conserved complementarity determining region 3. *J Exp Med* 174:1467–1476, 1991
  35. BEN-NUN A, LIBLAU R, COHEN L, LEHMANN D, TOURNIER-LASSERVE E, ROSENZWEIG A, JINGWU Z, RAUS J, BACH M: Restricted T-cell receptor V $\beta$  gene usage by myelin basic protein-specific T-cell clones in multiple sclerosis: Predominant genes vary in individuals. *PNAS (USA)* 88:2466–2470, 1991
  36. KOTZIN B, KARUTURI S, CHOU Y, LAFFERTY J, FORRESTER J, BETTER M, NEDWIN B, OFFNER H, VANDENBARK A: Preferential T-cell  $\beta$ -chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis. (abstract) *PNAS (USA)* 88:9161, 1991
  37. GEIGERICH G, PETTE M, EPPLER J, WEKERLE H, HANKANEN A: Diversity of T cell receptor  $\alpha$  and  $\beta$  chain genes expressed by human T cells specific for similar myelin basic protein/major histocompatibility complexes. *Eur J Immunol* 22:1331, 1992
  38. RICHERT J, ROBINSON E, JOHNSON A, BERGMAN C, DRAGOVIC L, REINSMOEN N, HURLEY C: Heterogeneity of the T cell receptor  $\beta$  gene rearrangements generated in myelin basic protein-specific T cell clones isolated from a patient with multiple sclerosis. *Ann Neurol* 29:299–306, 1991
  39. CLAYMAN MD, SUN MJ, MICHAUD L, BRILL DJ, RIBLET R, NEILSON EG: Clonotypic heterogeneity in experimental interstitial nephritis. Restricted specificity of the anti-tubular basement membrane B cell repertoire is associated with a disease-modifying crossreactive idio-type. *J Exp Med* 167:1296–1312, 1988
  40. HEEGER P, WOLF G, NEILSON EG: The pathogenesis of tubulointerstitial nephritis, in *Nephrology*, edited by HATANO, Tokyo, Springer-Verlag, 1991, pp 151–164
  41. KUCHROO V, SOBEL R, LANING J, MARTIN C, GREENFIELD E, DORF M, LEES M: Experimental allergic encephalomyelitis mediated by clones T cells specific for a synthetic peptide of myelin proteolipid protein. *J Immunol* 148:3776–3782, 1992
  42. RANSOHOFF R, TOUHY V, LEHMANN P: The immunology of multiple sclerosis: New intricacies and new insights. *Curr Opin Neurol* 7:242–249, 1994
  43. SERCARZ E, LEHMAN P, AMETANI A, BENICHOU G, MILLER A, MOUDGIL K: Dominance and crypticity of T cell antigenic determinants. *Ann Rev Immunol* 11:729–766, 1993
  44. LEHMANN P, FORSTHUBER T, MILLER A, SERCARZ E: Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. *Nature* 358:155–157, 1992
  45. SKUNDRIK D, KIM C, TSE H, RAINE C: Homing of T cells to the central nervous system throughout the course of relapsing experimental autoimmune encephalomyelitis in Thy-1 congenic mice. *J Neuroimmunol* 46:113–121, 1993
  46. O'MARA T, RAINE C: Chronologic localization of myelin-reactive cells in the lesions of relapsing EAE: Implications for the study of multiple sclerosis. *Neurology* 43:1028–1033, 1993
  47. KARIN N, SZAFAER F, MITCHELL D, GOLD D, STEINMAN L: Selective and nonselective stages in homing of T lymphocytes to the central nervous system during experimental allergic encephalomyelitis. *J Immunol* 150:4116–4124, 1993
  48. LOUIE M, NELSON C, LOH D: Identification and characterization of new murine T cell receptor  $\beta$  chain variable region genes. *J Exp Med* 170:1987–1998, 1989
  49. LAMONT A, SETTE A, FUJINAMI R, CONON S, MILES C, GREY H: Inhibition of experimental autoimmune encephalomyelitis induction in SJL/J mice by using a peptide with high affinity for I-A<sup>s</sup> molecules. *J Immunol* 145:1687–1693, 1993
  50. HOWELL M, WINTERS S, OLEE T, POWELL H, CARLO D, BROSTOFF S: Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. *Science* 246:668–670, 1989